Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.8 EUR
191.04 M EUR
1.90 B EUR
171.58 M
About ROHTO PHARMACEUTICAL CO
Sector
Industry
CEO
Kunio Yamada
Website
Headquarters
Osaka
Founded
1899
ISIN
JP3982400008
FIGI
BBG01TZ3PFX3
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. Its products include eye drops, contact lens care, dermal medicines, skin care, internal medicines, cold remedies, test kits, and denture cleansers. Its operations are carried out through the following segments: Japan, America, Europe, Asia, and Others. The company was founded by Anmin Yamada on February 22, 1899 and is headquartered in Osaka, Japan.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UC1 is 11.8 EUR — it has decreased by −0.84% in the past 24 hours. Watch ROHTO PHARM. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ROHTO PHARM. stocks are traded under the ticker UC1.
UC1 stock hasn't changed in a week, the month change is a −5.60% fall, over the last year ROHTO PHARM. has showed a 90.23% increase.
We've gathered analysts' opinions on ROHTO PHARM. future price: according to them, UC1 price has a max estimate of 20.31 EUR and a min estimate of 10.15 EUR. Watch UC1 chart and read a more detailed ROHTO PHARM. stock forecast: see what analysts think of ROHTO PHARM. and suggest that you do with its stocks.
UC1 stock is 0.85% volatile and has beta coefficient of 0.49. Track ROHTO PHARM. stock price on the chart and check out the list of the most volatile stocks — is ROHTO PHARM. there?
Today ROHTO PHARM. has the market capitalization of 2.72 B, it has increased by 1.24% over the last week.
Yes, you can track ROHTO PHARM. financials in yearly and quarterly reports right on TradingView.
ROHTO PHARM. is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ROHTO PHARM. revenue for the last quarter amounts to 509.75 M EUR, despite the estimated figure of 536.30 M EUR. In the next quarter, revenue is expected to reach 461.78 M EUR.
UC1 net income for the last quarter is 38.20 M EUR, while the quarter before that showed 73.02 M EUR of net income which accounts for −47.68% change. Track more ROHTO PHARM. financial stats to get the full picture.
ROHTO PHARM. dividend yield was 1.61% in 2024, and payout ratio reached 26.45%. The year before the numbers were 0.91% and 19.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 20, 2025, the company has 9.14 K employees. See our rating of the largest employees — is ROHTO PHARM. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROHTO PHARM. EBITDA is 317.99 M EUR, and current EBITDA margin is 16.72%. See more stats in ROHTO PHARM. financial statements.
Like other stocks, UC1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROHTO PHARM. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROHTO PHARM. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROHTO PHARM. stock shows the buy signal. See more of ROHTO PHARM. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.